Novo Nordisk Shares Plunge 8% on Disappointing Long-Term Growth Outlook Despite Ambitious Obesity Drug Pipeline Through 2035

Novo Nordisk shares tumbled 8 percent on September 21, 2026, after the Danish pharmaceutical giant unveiled its long-term strategy at a capital markets day in London, with investors expressing disappointment that the company's growth targets failed to ease concerns about its ability to compete in the increasingly crowded weight-loss drug market. The company announced plans to launch more than five new products with blockbuster potential by 2030 and expects pipeline sales to exceed 150 billion Danish kroner, approximately $23 billion, by 2035. However, Novo said it expects compound annual revenue growth between 2026 and 2030 to be in line with industry peers while maintaining a broadly stable operating margin, a projection analysts viewed as underwhelming given the company's historic dominance in the GLP-1 obesity and diabetes market. Investor skepticism centered on whether Novo can defend its market position as competitors including Eli Lilly ramp up their own obesity franchises and as the company faces patent expiration pressures on flagship products like Ozempic. Per Hansen, savings economist at Nordnet, told CNBC that investors had hoped for a miracle project that could turn momentum around in the short term, adding that for obvious reasons that miracle does not exist. The NYSE ADR closed Friday September 18 at approximately $43.23 to $43.40 before opening sharply lower Monday, with the decline wiping billions off the company's market capitalization of around $193 billion. Novo emphasized that its targets represent strategic ambitions rather than formal financial guidance, and in August had already cautioned that it expects adjusted sales and operating profit to both be down 6 percent to flat in 2026 at constant exchange rates. The bearish reaction underscores the challenge facing Novo as it seeks to diversify beyond semaglutide-based therapies, which analysts estimate contribute approximately 75 percent of 2026 sales, while managing investor expectations in a c